Lexaria Bioscience Corp. (CSE:LXX, OTCQX:LXRP), (the “Company” or “Lexaria”) an innovator in drug delivery platforms, announces the successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”) to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECHTM technology.

A primary goal of the R&D Program was to determine whether Lexaria’s DehydraTECH technology causes the formation of a new molecular entity (“NME”) through its processing. The Company is very pleased to report that all evidence aligns that no covalent-bonded NME is created with Lexaria’s technology. Technologies or processes, including certain forms of nanotechnology, that do create an NME are often burdened with much more extensive regulatory hurdles from agencies such as the FDA or Health Canada, to prove that the NME is safe for human consumption.

The R&D Program involved the preparation of over 50 formulations utilizing Lexaria’s DehydraTECH methodology and 33 of these were selected for in-depth analytical examination. Active pharmaceutical ingredients (“APIs”) tested included both THC and CBD from cannabis extract, pure nicotine, nicotine polacrilex, and pure ibuprofen. Formulations also tested both long chain fatty acid (“LCFA”) and a medium chain triglyceride (“MCT”) oils (as well as combinations of both oils together).

Analytical work included extensive use of liquid chromatography high-resolution mass spectrometry (“LC-HRMS”), nuclear magnetic resonance (“NMR”), and Fourier transform infrared (“FTIR”) spectroscopy. NMR was utilized as the main analytical technique due to its quantitative nature and ability to directly characterize the molecular construction of formulated products. The NMR and FTIR analyses demonstrated no shift in the spectral positioning of the API’s for all formulations tested, providing nearly incontrovertible evidence of a lack of any covalent-bonded NME.

In a 2016 report from the American Dental Association (www.ada.org) it was noted that 354 of 379 (or 93%) popular beverages commonly sold in retail stores, have a mildly acidic pH of 4.0 or lower. Many flavored beverage products from Gatorade, Powerade, Dasani and others have a pH of 2.73 to 3.05. The R&D program also tested Lexaria’s formulations at highly acidic levels of pH 1.12 and mildly acidic levels of pH 4.82, and the Company is delighted to report no chemical modification or presence of degradation of the API’s for both of the formulation classes analysed in this aspect of the program: cannabinoids and nicotine polacrilex.

Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage. Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats and Lexaria’s technology is now proven capable of doing so.

The R&D Program was first announced on February 8, 2017, and although the specific goals within it have been achieved, an ongoing working relationship continues between the NRC and the Company to achieve new objectives. Additional studies underway with the NRC include studying nicotine polacrilex formulations for purposes of determining what other interactions may be occurring at a molecular level between the API and the fatty acids used in the DehdyraTECH™ processing methodology that may contribute to the improved pharmacology/performance of DehydraTECH™ formulations and our understanding thereof.

Lexaria extends its thanks to the talented and hard-working men and women at the NRC for their dedication and thorough scientific evaluation of Lexaria’s groundbreaking and patented DehydraTECH technology and formulations.

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Click here to connect with Lexaria Bioscience Corp. (CSE:LXX, OCT:LXRP) for an Investor Presentation.

Source: www.accesswire.com

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less